Recent Quotes
My Watchlist
Indicators
Investor Uprising 25
Overview
News
Currencies
International
Treasuries

Articles published by Marinus Pharmaceuticals

< Previous 1 2 3 4 Next >
Marinus Pharmaceuticals Announces Topline Results From Phase 3 TrustTSC Trial of Oral Ganaxolone in Tuberous Sclerosis Complex and Commences Process to Explore Strategic Alternatives
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Presents Clinical Data From Pivotal Phase 3 RAISE Trial in Refractory Status Epilepticus at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Further Strengthens Intellectual Property Estate with Method of Treatment Patent for ZTALMY® Titration Regimens
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Podium and Poster Presentations at the Neurocritical Care Society 2024 Annual Meeting
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Highlight Clinical Progress and Commercial Launch Preparedness for ZTALMY® in TSC at Investor and Analyst Day
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Second Quarter 2024 Financial Results on August 13, 2024
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated with CDKL5 Deficiency Disorder
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Topline Results from Phase 3 RAISE Trial of IV Ganaxolone in Refractory Status Epilepticus
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report First Quarter 2024 Financial Results on May 8, 2024
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2023 ZTALMY® Net Product Revenue and Provides Business Update
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Seven Presentations at AES 2023, New Publication in Epilepsia and Results From the Second Generation Formulation MAD Study
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Marinus Pharmaceuticals
Via Business Wire
Tickers MRNS
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.